Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy.
This paper reviews recent progress in the design and evaluation of MEK inhibitors as cancer therapeutics. Activation of the Ras / Raf / MEK / MAP kinase pathway has been implicated in uncontrolled cell proliferation and tumor growth. Mutated, oncogenic forms of Ras are found in 50% of colon, 90% of pancreatic and 30% of lung cancers. Recently, B-Raf mutations have been identified in more than 60% of malignant melanomas and from 40-70% of papillary thyroid cancers. MEK, a dual specificity kinase, is a key player in this pathway; it is downstream of both Ras and Raf and activates ERK1/2 through phosphorylation of key tyrosine and threonine residues. Representative examples of both ATP competitive and non-competitive inhibitors as well as natural product based inhibitors will be discussed.
Wallace
Eli M
EM
Array BioPharma Inc., 3200 Walnut Street, Boulder, CO 80301, USA. Eli.Wallace@arraybiopharma.com
Lyssikatos
Joseph P
JP
Yeh
Tammie
T
Winkler
James D
JD
Koch
Kevin
K
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D001685:Biological Factors; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D015398:Signal Transduction / Q000187:drug effects
D000970:Antineoplastic Agents; D001685:Biological Factors; D004791:Enzyme Inhibitors; D020930:MAP Kinase Kinase Kinases